Related Experiment Videos
cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma
Cancer Treatment Reports
|February 1, 1978
Summary
Cis-dichlorodiammineplatinum(II) (DDP) shows effectiveness in treating advanced osteogenic sarcoma, with significant responses observed in patients with metastatic disease. Despite toxicities like kidney damage, DDP offers a new treatment option.
Area of Science:
- Oncology
- Pharmacology
Background:
- Osteogenic sarcoma is a challenging bone cancer, often requiring aggressive treatment for metastatic disease.
- Previous treatments like surgery, adriamycin (ADR), and high-dose methotrexate have limitations in managing advanced cases.
Purpose of the Study:
- To evaluate the efficacy and toxicity of cis-dichlorodiammineplatinum(II) (DDP) in patients with advanced metastatic osteogenic sarcoma.
- To assess DDP as a potential new chemotherapeutic agent for this condition.
Main Methods:
- Eight patients with advanced metastatic osteogenic sarcoma received cis-dichlorodiammineplatinum(II) (DDP) therapy.
- Patients had prior treatments including amputations, adriamycin (ADR), and high-dose methotrexate.
Main Results:
- One complete response (pulmonary metastases) and four partial responses (lung and bone metastases) were observed.
- One patient with local recurrence achieved disease-free status for over 3 years after surgery and DDP.
- Common toxicities included nausea, vomiting, irreversible kidney damage in two patients, and transient severe hematologic suppression in two patients.
Conclusions:
- Cis-dichlorodiammineplatinum(II) (DDP) demonstrates efficacy in treating advanced metastatic osteogenic sarcoma.
- DDP represents a new and effective therapeutic option for osteogenic sarcoma, though careful monitoring for toxicity is necessary.